ArticleFrontiers in oncology2026

Challenges in employing overall survival as a primary outcome in ovarian cancer studies: insights from PARP inhibitor trials.

Yoav Siegler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.